Access to Anti-Cancer Drugs in India: Is There a Need to Revise Reimbursement Policies?
CONCLUSIONS: Policy makers should consider addition of newer treatments, exclusion of sub-optimal treatments, increments in per patient budget and optimization of supportive care, which may contribute to improvements in survival and quality of life for Indian cancer patients.
PMID: 29466887 [PubMed - as supplied by publisher]
Source: Expert Review of Pharmacoeconomics and Outcomes Research - Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Erbitux | Gastric (Stomach) Cancer | Gastroenterology | Health Management | Herceptin | India Health | Study | Tarceva